“Amgen has been present in Romania through a therapeutics program for few years, and its products have been available at local distributors since 2004”, said Regis Lhomme (photo), chief executive of Amgen Romania.

He added that the opening a wholly-owned subsidiary in Romania will increase the number of patients who will benefit of the novel biotech medicines manufactured by Amgen.

Regis Lhomme’s six-year term ended in 2006, when he assumed leadership of Pfizer’s operations in Russia. As of 2010, Lhomme serves as chief executive of Amgen Romania.

Amgen is a leading human therapeutics company in the biotechnology industry. Biotechnology medicine consists of novel and efficient products and treatment against serious illness such as cancer, kidney disease and osteoporosis. Biotech products account for 20% of the medicines currently in the market. Moreover, the majority of the newest therapeutic techniques are based on genetic engineering, the company said.

“Amgen is looking forward to collaborating with the Romanian science community and with the government in Romania, in order to facilitate Romanian patients’ access to biotech medicine”, said Rolf Hoffman, Senior Vice President, International Commercial Operations, Amgen International.

Amgen reported revenues from its global operations of $14.6 billion, and expects $15.1 – 15.5 billion.